{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:42:09Z","timestamp":1794606129720,"version":"4.9.1"},"reference-count":43,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,10,8]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>Glioblastoma (GBM) remains the most lethal primary brain cancer with a median survival of under 2 years despite current best treatment practices. Early immunotherapies, including checkpoint blockade and vaccines, showed safety and immunogenicity but no survival benefit. Chimeric antigen receptor (CAR) T treatments in GBM trials have yielded feasibility and antitumor signals but still lack long-term control. This review synthesizes recent clinical and mechanistic data to establish priorities for clinical trial design, patient selection, and treatment development aimed at achieving durable responses in GBM.<\/jats:p>\n                  <jats:p>Recent trials highlight two consistent observations regarding the delivery of CAR T treatment. First, that CAR T cells can be effectively delivered peripherally rather than requiring direct intracranial administration. And second, multi-antigen, regionally delivered products can induce measurable intracranial responses. These findings indicate that access across the blood-brain barrier is feasible, but persistent function is limited by tumor antigen heterogeneity and an immunosuppressive, myeloid-dominated microenvironment that accelerates T-cell exhaustion.<\/jats:p>\n                  <jats:p>Emerging development strategies reflect these constraints. Broader antigen recognition is being pursued through bivalent and engager-secreting constructs. Locoregional delivery through cerebrospinal fluid spaces enables repeated exposure at multifocal sites. Resistance modules targeting TGF-\u03b2 (Transforming Growth Factor-beta) signaling and myeloid suppression are being investigated to prolong persistence. Cerebrospinal fluid pharmacodynamic monitoring, such as measuring cytokines, chemokines, and CAR cell kinetics, may support adaptive dosing and minimize corticosteroid use. Patient selection criteria increasingly favor individuals with confirmed target expression, sufficient intratumoral T-cell infiltration, and minimal steroid exposure.<\/jats:p>\n                  <jats:p>Advances in manufacturing, including point-of-care platforms, allogeneic products, and in vivo CAR engineering, aim to shorten production timelines and improve access. Collectively, regional delivery, multi-antigen recognition, and microenvironment resistance constitute the current framework for translating CAR T therapy in GBM from transient responses toward sustained benefit.<\/jats:p>","DOI":"10.1136\/jitc-2025-012308","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:35:24Z","timestamp":1761975324000},"page":"e012308","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct03726515","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05660369","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05168423","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02208362","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04185038","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04196413","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01454596","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05660369","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05168423","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02208362","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01109095","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04185038","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04196413","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03423992","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Chase M","family":"Walton","sequence":"first","affiliation":[{"name":"Neurosurgery, Medical University of South Carolina, Charleston, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Bell","sequence":"additional","affiliation":[{"name":"Neurosurgery, Medical University of South Carolina, Charleston, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"O\u2019Neil","sequence":"additional","affiliation":[{"name":"Immunology, Medical University of South Carolina, Charleston, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur","family":"Sahin","sequence":"additional","affiliation":[{"name":"Biochemistry, Medical University of South Carolina, Charleston, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan D","family":"Choi","sequence":"additional","affiliation":[{"name":"Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E","family":"Fecci","sequence":"additional","affiliation":[{"name":"Neurosurgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben A","family":"Strickland","sequence":"additional","affiliation":[{"name":"Neurosurgery, Medical University of South Carolina, Charleston, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2025111301353402000_13.10.e012308.1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11060-025-04946-w","article-title":"Long-term survival, patterns of progression, and patterns of use for patients with newly diagnosed glioblastoma treated with or without Tumor Treating Fields (TTFields) in a real-world setting","volume":"173","author":"Riegel","year":"2025","journal-title":"J Neurooncol"},{"key":"2025111301353402000_13.10.e012308.2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21586"},{"key":"2025111301353402000_13.10.e012308.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02893-z"},{"key":"2025111301353402000_13.10.e012308.4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13046-025-03431-6","article-title":"CD70 CAR-T cells empowered by TS-2021 through ex vivo transduction show potent antitumor efficacy against glioblastoma","volume":"44","author":"Fang","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"2025111301353402000_13.10.e012308.5","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102676","article-title":"Preclinical efficacy of multi-targeting mRNA-based CAR T cell therapy in resection models of glioblastoma","volume":"36","author":"Dagher","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"2025111301353402000_13.10.e012308.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.11.026"},{"key":"2025111301353402000_13.10.e012308.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02875-1"},{"key":"2025111301353402000_13.10.e012308.8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009486","article-title":"EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses","volume":"12","author":"Lertsumitkul","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2025111301353402000_13.10.e012308.9","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-025-06475-6","article-title":"Efficacy of MET-targeting CAR T cells against glioblastoma patient-derived xenograft models","volume":"23","author":"Qin","year":"2025","journal-title":"J Transl Med"},{"key":"2025111301353402000_13.10.e012308.10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","article-title":"Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial","volume":"5","author":"Bagley","year":"2024","journal-title":"Nat Cancer"},{"key":"2025111301353402000_13.10.e012308.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314390"},{"key":"2025111301353402000_13.10.e012308.12","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat Med"},{"key":"2025111301353402000_13.10.e012308.13","doi-asserted-by":"crossref","first-page":"1632122","DOI":"10.3389\/fcell.2025.1632122","article-title":"Interactions between glioblastoma and myeloid cells","volume":"13","author":"Li","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"2025111301353402000_13.10.e012308.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0192-1"},{"key":"2025111301353402000_13.10.e012308.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.07.020"},{"key":"2025111301353402000_13.10.e012308.16","doi-asserted-by":"crossref","first-page":"9718","DOI":"10.1038\/s41467-024-54129-w","article-title":"Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRP\u03b3-derived CD47 blocker","volume":"15","author":"Martins","year":"2024","journal-title":"Nat Commun"},{"key":"2025111301353402000_13.10.e012308.17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"2025111301353402000_13.10.e012308.18","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000260"},{"key":"2025111301353402000_13.10.e012308.19","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/neuonc\/noae126","article-title":"IL-13R\u03b12\/TGF-\u03b2 bispecific CAR-T cells counter TGF-\u03b2-mediated immune suppression and potentiate anti-tumor responses in glioblastoma","volume":"26","author":"Hou","year":"2024","journal-title":"Neuro Oncol"},{"key":"2025111301353402000_13.10.e012308.20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc8362"},{"key":"2025111301353402000_13.10.e012308.21","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature New Biol"},{"key":"2025111301353402000_13.10.e012308.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.06.024"},{"key":"2025111301353402000_13.10.e012308.23","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0750"},{"key":"2025111301353402000_13.10.e012308.24","doi-asserted-by":"crossref","unstructured":"Jiang C , Xu H , Shentu J , et al . GD2-CAR T Cell Therapy for H3K27M+ Diffuse Intrinsic Pontine Glioma: A Phase I Clinical Trial and Mechanistic Insights. Immunology 2025. doi:10.1111\/imm.70019","DOI":"10.22541\/au.174247564.46678816\/v1"},{"key":"2025111301353402000_13.10.e012308.25","doi-asserted-by":"publisher","DOI":"10.2174\/1568009053765780"},{"key":"2025111301353402000_13.10.e012308.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.04.009"},{"key":"2025111301353402000_13.10.e012308.27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1434495","article-title":"EGFRVIII and EGFR targeted chimeric antigen receptor T cell therapy in glioblastoma","volume":"14","author":"Sterner","year":"2024","journal-title":"Front Oncol"},{"key":"2025111301353402000_13.10.e012308.28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009403","article-title":"EphA3 CAR T cells are effective against glioblastoma in preclinical models","volume":"12","author":"Martins","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2025111301353402000_13.10.e012308.29","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2011.538682"},{"key":"2025111301353402000_13.10.e012308.30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1788"},{"key":"2025111301353402000_13.10.e012308.31","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03481-0"},{"key":"2025111301353402000_13.10.e012308.32","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30468-X"},{"key":"2025111301353402000_13.10.e012308.33","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac116"},{"key":"2025111301353402000_13.10.e012308.34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12885-017-3148-1","article-title":"In search of druggable targets for GBM amino acid metabolism","volume":"17","author":"Panosyan","year":"2017","journal-title":"BMC Cancer"},{"key":"2025111301353402000_13.10.e012308.35","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1172\/JCI138649","article-title":"Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme","volume":"130","author":"Smith","year":"2020","journal-title":"J Clin Invest"},{"key":"2025111301353402000_13.10.e012308.36","doi-asserted-by":"publisher","DOI":"10.1227\/01.NEU.0000360379.95800.2F"},{"key":"2025111301353402000_13.10.e012308.37","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10071738","article-title":"Site-Specific Considerations on Engineered T Cells for Malignant Gliomas","volume":"10","author":"Elmadany","year":"2022","journal-title":"Biomedicines"},{"key":"2025111301353402000_13.10.e012308.38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.872756","article-title":"PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"2025111301353402000_13.10.e012308.39","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10716","article-title":"Advances in bioengineered CAR T\/NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology-based strategies for enhanced CAR T\/NK cell therapy","volume":"10","author":"Dana","year":"2025","journal-title":"Bioeng Transl Med"},{"key":"2025111301353402000_13.10.e012308.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.07.015"},{"key":"2025111301353402000_13.10.e012308.41","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316595"},{"key":"2025111301353402000_13.10.e012308.42","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/10668969241239679","article-title":"Glioblastoma, IDH-Wildtype With Epithelioid Morphology and a BCR::NTRK2 Fusion","volume":"33","author":"Umeres-Francia","year":"2025","journal-title":"Int J Surg Pathol"},{"key":"2025111301353402000_13.10.e012308.43","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s43018-021-00201-z","article-title":"Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas","volume":"2","author":"Friedrich","year":"2021","journal-title":"Nat Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T09:36:13Z","timestamp":1763026573000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,31]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/jitc-2025-012308"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012308","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]}}}